, Ronald S. Mead 1, 11, 12 , Qinying Xu , James G. Kench 1, 17, 18 , Neil D. Merrett 5, 19 , Christopher W. Pancreatic cancer is molecularly diverse, with few effective therapies. Increased mutation burden and defective DNA repair are associated with response to immune checkpoint inhibitors in several other cancer types. We interrogated 385 pancreatic cancer genomes to define hypermutation and its causes. Mutational signatures inferring defects in DNA repair were enriched in those with the highest mutation burdens. Mismatch repair deficiency was identified in 1% of tumors harbouring different mechanisms of somatic inactivation of MLH1 and MSH2. Defining mutation load in individual pancreatic cancers and the optimal assay for patient selection may inform clinical trial design for immunotherapy in pancreatic cancer.
Pancreatic ductal adenocarcinoma (PDAC) has a 5-year survival of less than 5% with therapies offering only incremental benefit 1 , potentially due to the diversity of its genomic landscape [2] [3] [4] . Recent reports link high mutation burden with response to immune checkpoint inhibitors in several cancer types 5 , Defining tumors that are hypermutated with an increased mutation burden and understanding the underlying mechanisms in pancreatic cancer has the potential to advance therapeutic development, particularly for immunotherapeutic strategies.
Whole genome (WGS, n=180) and whole exome (n=205) sequencing of 385 unselected predominantly sporadic PDAC (Supplementary Table 1 ) defined an average mutation load of 1.8 and 1.1 mutation per megabase (Mb) respectively (Supplementary Table 2 ). Outlier analysis identified 20 samples with the highest mutation burden (5.2%, 15 WGS and 5 exome) ( Table 1 and Supplementary Figure 1A) , 5 of which were considered extreme outliers and classified as hypermutated as they contained ≥12 somatic mutations/Mb, the defined threshold for hypermutation in colorectal cancer 6 . Immunohistochemistry (IHC) for mismatch repair (MMR) proteins (MSH2, MSH6, MLH1 and PMS2) identified 4 MMR deficient tumors, all of which were hypermutated (n = 180, Figure 1 ).
KRAS mutation status and histopathological characteristics have been associated with MMR deficient pancreatic tumors 7 . Of the 4 MMR deficient tumors in our cohort, 2 were KRAS wild type; 3 had undifferentiated to moderately differentiated histology and one a signet-ring component. These features were not predictive of MMR deficiency in our cohort as 11 additional non-MMR deficient tumors had a signet-ring cell component or colloid histology and 131 of 347 assessable tumors had poorly-or un-differentiated histology.
Mutational signature analysis can detect MMR deficiency indirectly based on somatic mutations 8 . An MMR deficient signature dominated the MMR deficient tumors (with WGS), and was minimal in MMR intact tumors (Supplementary Figure 1) . In addition, microsatellite instability (MSI), a hallmark of MMR deficiency in colorectal cancer, was detected in all three MMR deficient tumors with WGS using MSIsensor 9 (Supplementary Table 2 ). MSI was not identified for the fourth MMR deficient sample potentially due to the reduced number of microsatellite loci in exome data.
The underlying causes of MMR deficiency in the 4 cases were private somatic events. For 2 cases MSH2 was disrupted by different structural rearrangements, 1 case contained a missense MSH2 mutation and the last, methylation of the MLH1 promoter (Figure 1 ). The missense mutation caused an MSH2 splice acceptor site mutation that alters the same nucleotide reported to result in a pathogenic skipping of exon 13 in germline studies 10 . Hypermethylation of the MLH1 promoter is the predominant mechanism of MSI in sporadic colon cancer 11 . The remaining hypermutated tumor contained an intact MMR pathway, and was a cell line (ATCC, CRL-2551) with an unidentified mutational signature; therefore the high mutation burden in this sample may be the result of long term cell culture. ; 7 of these tumors contained high levels of genomic instability with >200 structural variants and mutations in genes involved in HR were present for 6/8 cases (Supplementary Table 2 ). In addition, one case that had undergone exome sequencing had a somatic BRCA2 nonsense mutation that likely contributed to HR deficiency in this sample. A mutational signature associated with T>G mutations at TT sites previously described in other cancers, including esophageal cancer 12 was the major contributor (>3 mutations/Mb) in 2 samples. For these two and the remaining 4 cases, no potential causative event could be identified.
Although germline defects in MMR genes are well reported in pancreatic cancer 13 in our cohort, they did not contribute to MMR deficiency even in those with familial pancreatic cancer or a personal or family history of Lynch-related tumors. A germline truncating variant was detected in PMS2 for 1 case but did not have loss of the second allele, therefore had normal IHC staining and did not display a MMR mutational signature (Supplementary Table 2 ). MMR deficiency is important in the evolution in a small, but meaningful proportion of pancreatic cancers with a prevalence of 1% (4/385) in our cohort. This is consistent with recent studies using the Bethesda PCR panel 14 , and with previous estimates of MSI prevalence of 2-3% 15 . However, in tumors with low epithelial content that underwent exome sequencing, the sensitivity of somatic mutation detection is reduced, which will affect mutation burden and signature analysis. Whilst cognizant of small numbers, immunohistochemistry was the most accurate in defining MMR due to multiple genomic mechanisms of MMR gene inactivation. Multiple methods to define MMR deficiency may be required for clinical trials that aim to recruit MMR deficient participants for clinical trials examining checkpoint inhibitors or other therapies in pancreatic cancer. Homologous recombination deficient tumors, and those with a novel signature seen in esophageal cancer had an increased mutation burden, and need further evaluation as potential patient selection markers for clinical trials of checkpoint inhibitor and other therapies that target tumors with a high mutation burden. 
